KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Assets (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Non-Current Assets for 13 consecutive years, with $167.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 5.52% year-over-year to $167.6 million, compared with a TTM value of $685.5 million through Dec 2025, down 5.02%, and an annual FY2025 reading of $167.6 million, down 5.52% over the prior year.
  • Non-Current Assets was $167.6 million for Q4 2025 at Travere Therapeutics, roughly flat from $167.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $203.3 million in Q1 2023 and bottomed at $167.5 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $185.8 million, with a median of $186.1 million recorded in 2022.
  • The sharpest move saw Non-Current Assets grew 19.57% in 2021, then fell 10.26% in 2024.
  • Year by year, Non-Current Assets stood at $193.8 million in 2021, then dropped by 3.95% to $186.1 million in 2022, then dropped by 7.53% to $172.1 million in 2023, then grew by 3.07% to $177.4 million in 2024, then dropped by 5.52% to $167.6 million in 2025.
  • Business Quant data shows Non-Current Assets for TVTX at $167.6 million in Q4 2025, $167.5 million in Q3 2025, and $175.7 million in Q2 2025.